Brandi Maria Luisa
Bone and Mineral Metabolic Unit, Department of Internal Medicine and Careggi Hospital, University of Florence, Florence, Italy.
Discov Med. 2010 Sep;10(52):209-12.
Paget's Disease of Bone (PDB) is the second most common metabolic bone disease following osteoporosis. PDB is characterized by an increase in bone resorption and bone deposition. For this reason antiresorptives were indicated as the ideal therapy for PDB. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more convenient management of this disorder. However, no firm evidence exists to show that bisphosphonates can prevent the complications of PDB, and further work is needed to evaluate the influence of pharmacological therapy on long-term clinical outcomes, so that clinicians can make better-informed choices about the risks and benefits of treatment. This article will focus on the present status and future pharmacological developments in PDB.
骨佩吉特病（PDB）是仅次于骨质疏松症的第二常见代谢性骨病。PDB的特征是骨吸收和骨沉积增加。因此，抗吸收药物被认为是PDB的理想治疗方法。最近，更新、更强效的含氮双膦酸盐的出现改善了治疗效果，使这种疾病的管理更加便捷。然而，尚无确凿证据表明双膦酸盐可以预防PDB的并发症，需要进一步开展工作来评估药物治疗对长期临床结局的影响，以便临床医生能够在更充分了解情况的基础上对治疗的风险和益处做出更好的选择。本文将聚焦于PDB的现状及未来药物研发进展。
